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A canine model was developed to investigate coronary 
artery thromholysis and reocclusion in the setting of endo- 
thelial cell damage and fixed stenosis, which simulate 
anatomic features occurring in patients with acute myocar- 
dial infarction. In open chest dogs, endothelial cell damage 
was produced in the left anterior descending coronary 
artery by external compression with blunt forceps, >90% 
stenosis was obtained by an external constrictor and throm- 
bosis was induced by instillation of thrombin and fresh 
blood in an isolated arterial segment. 
In the absence of stenosis, intravenous infusion of 
750,000 U of streptokinase over 1 h caused reperfusion in 
five of six dogs in 34 + 25 min (mean f SD). Urokinase, 
600,000 U intravenously over 30 min followed by 600,000 U 
over 30 min by the intracoronary route, induced reperfu- 
sion in three of four dogs in 65 + 23 min. Recombinant two 
chain tissue-type plasminogen activator @t-PA) (G11021), 
infused intravenously at a rate of 15 pg/kg per min for 30 
min or until reflow, induced reperfusion in all 12 dogs in 
28 + 13 min. In the absence of coronary artery stenosis, 
spontaneous reocclusion did not occur within 2 h after the 
end of the infusion. 
In the presence of the coronary artery constrictor, 
which reduced the blood flow to 40 2 10% of baseline, 
streptokinase, urokinase and rt-PA caused coronary throm- 
bolysis to proceed at comparable or only slightly slower 
rates. Cyclical reocclusion during or after the end of 
infusion of these thrombolytic agents, caused by platelet- 
rich thrombus, was almost invariably observed, generally 
within 30 min after the onset of reperfusion. 
It is concluded that this canine model simulates several 
characteristic features of coronary artery thrombosis in 
human patients and, therefore, appears to be useful for the 
study of both the potency of thrombolytic agents and 
strategies for the prevention of reocclusion after coronary 
artery thrombolysis. 
(J Am Co11 Cardiol1989;13:1409-14) 
Reperfusion of the coronary artery may salvage ischemic 
myocardium if it is achieved soon after the onset of the 
occlusion (1,2). Reperfusion is unlikely to be of significant 
benefit, however, if the vessel rapidly reoccludes. Studies 
from our institution and others (3-5) have indicated that after 
successful coronary artery thrombolysis, rapid reocclusion 
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occurs in approximately 25% of patients despite hepariniza- 
tion. The major predictor of reocclusion is a residual high 
grade stenosis (>80%) of the reperfused vessel (45. Be- 
cause acute coronary artery thrombosis is usually superim- 
posed on chronic atherosclerosis, it is likely that much of 
this residual stenosis is due to the fixed atherosclerotic 
narrowing rather than to mural thrombus. Reocclusion has 
been prevented by either percutaneous transluminal coro- 
nary angioplasty (6) or a maintenance infusion of recombi- 
nant human tissue-type plasminogen activator @t-PA) (5). 
To study the mechanism and to investigate new strategies 
to prevent reocclusion, we developed an experimental model 
in the dog, in which an acute thrombus in the left anterior 
descending coronary artery is superimposed on a fixed high 
grade constriction. The efficacy of thrombolytic agents in- 
cluding streptokinase, urokinase and rt-PA was evaluated in 
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this model and compared with their efficacy in the absence of 
the superimposed stenosis. 
Methods 
Animal models. Two coronary artery thrombosis models, 
with and without superimposed stenosis, were studied. The 
model without stenosis has been described elsewhere (I). 
The model with superimposed stenosis was produced as 
follows. Adult mongrel dogs (20 to 25 kg) were anesthetized 
with pentobarbital(30 mg/kg body weight intravenously) and 
additional doses as required. The dogs were intubated and 
placed on a respirator with a tidal volume of 10 to 15 ml/kg. 
Procainamide, 1.5 g intramuscularly, and lidocaine, 0.1 mgl 
kg per min intravenously, were given for prophylaxis of 
arrhythmias. The left carotid artery was exposed through an 
incision in the neck and cannulated with a no. 7-l Judkins 
coronary angiographic catheter. Thoracotomy was per- 
formed through the left fifth intercostal space, with cannu- 
lation of the left internal mammary artery for continuous 
blood pressure recording. The pericardium was opened and 
suspended to create a pericardial cradle. Epicardial electro- 
cardiographic (ECG) leads were placed for continuous ECG 
monitoring. The left anterior descending coronary artery 
was dissected out of the epicardium, and a 2.5 cm segment 
was isolated distal to the septal artery. A 0.7 mm internal 
diameter catheter was inserted into a side branch of the 
isolated left anterior descending coronary artery segment, 
and an electromagnetic flow meter (FM 501, Carolina Med- 
ical Electronics, King, North Carolina) was placed on the 
proximal portion of the artery for continuous blood flow 
monitoring. Selective angiography of the left anterior de- 
scending coronary artery was obtained using I to 2 ml of 
meglumine diatrizoate with videotape recording. One ml of 
blood was drawn for thrombus formation. 
The dog was then given heparin, 150 units/kg intrave- 
nously, followed by 50 units/kg per h to maintain the 
activated partial thromboplastin time at 2 to 2.5 times 
baseline. A 2 mm wide plastic wire tie (Mass Gas and 
Electric Supply) was progressively constricted around the 
left anterior descending coronary artery just distal to the 
proposed site of thrombus formation to limit the blood flow 
to 40 ? 10% of baseline. This animal model is schematically 
represented in Figure 1. This constriction corresponds to a 
>90% reduction in luminal diameter as determined by post- 
mortem angiography and quantitation of the degree of ste- 
nosis with the method of Brown et al. (7) (Fig. 2). A baseline 
angiogram was then performed. 
The isolated left anterior descending coronary artery 
segment was traumatized by four consecutive external com- 
pressions with blunt forceps during 3 to 5 s to promote 
thrombus adherence to the endothelium. Snare occlusions 
were made distal to the flow probe and proximal to the 
constriction site. Thrombin, 0.1 ml of 100 units/ml (Parke 
Electromognetlc 
Figure 1. Schematic representation of the experimental preparation 
of a thrombus in the left anterior descending coronary artery (LAD) 
with a distal high grade stenosis and a proximal electromagnetic 
blood flow probe. For further details, see text. 
Davis Topical Thrombin) mixed with 0.3 ml of blood was 
injected through the side branch catheter into the emptied 
coronary artery segment. After 5 min, the proximal snare 
was released and, 2 min later, the distal tourniquet. The side 
branch catheter was removed, whereas the permanent con- 
strictor remained in place. An angiogram was performed 30 
min after thrombus formation to confirm total occlusion of 
the artery, as demonstrated by the electromagnetic flow 
probe. Dogs with incomplete thrombosis were not used for 
further experiments. 
Infusion protocols. The thrombolytic agents were infused 
through a hind leg vein or directly through the coronary 
angiographic catheter into the left anterior descending coro- 
nary artery with use of a Harvard infusion pump. Angio- 
Figure 2. Postmortem coronary angiogram of a dog in which the 
external constriction reduced the blood flow to 40% of baseline. The 
angiographic stenosis is >90’%. 
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Figure 3. Schematic representation of coro- 
nary artery reperfusion/reocclusion cycles in 
the coronary artery thrombosis model (n = 25) 
with superimposed stenosis after infusion of 
streptokinase, urokinase or II-PA for 60 min. 
Hatched bar = occlusion; open bar = reperfu- 
sion. 
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grams were performed every 15 min to monitor occlusion 
and additionally when the flow probe showed evidence of 
reflow. The infusion of thrombolytic agent was continued for 
60 min, and the reflow was monitored both angiographically 
and by flow probe for at least 30 min after completion of the 
infusion. 
The reperfusion time was recorded as the time from the 
beginning of the infusion until reperfusion was documented 
by both the return of blood flow in the artery to ~50% of that 
before thrombus formation and complete angiographic filling 
of the apex with rapid clearance of the dye in ~4 heartbeats. 
After reperfusion was obtained, blood flow was monitored 
for evidence of reocclusion, with the final confirmation 
obtained by angiography. The reocclusion time was defined 
as the interval between documented reperfusion and reoc- 
elusion. Frequently, cyclical reperfusion occurred, inter- 
spersed with periods of reocclusion (Fig. 3). 
Blood analyses. Venous blood samples for hemostasis 
analysis were drawn on 0.01 M citrate and 150 kallikrein 
inhibitor units of aprotininjml for analysis of fibrinogen by a 
coagulation rate assay (1) that is insensitive to therapeutic 
concentrations of heparin. Blood samples were kept on ice 
until the end of the experiment, then centrifuged at room 
temperature and stored at -20°C until analyzed. 
Thrombolytic agents. Streptokinase was purchased from 
Hoechst-Roussel Pharmaceuticals, urokinase (Winkinase) 
was a gift of Dr. E. Murano (Bureau of Biologics, Bethesda, 
Maryland) and rt-PA (either G11021 containing predomi- 
nantly two chain rt-PA or G11035 consisting mainly of single 
chain rt-PA) was supplied by Genentech, Inc. 
The thrombolytic agents were infused at the following 
rates: Streptokinase, 750,000 units intravenously over 60 
min; urokinase, 600,000 units over 30 min intravenously, 
followed by 600,ooO units over 30 min through the Judkins 
catheter in the left anterior descending coronary artery; two 
chain rt-PA (G11021) intravenously at a rate of I5 ,cLg/kg per 
min for 30 min or until reflow in dogs without coronary 
artery stenosis, and at a rate of 15 pg/kg per min for 30 min 
followed by 7.5 pg/kg per min for 30 min intravenously in 
dogs with coronary artery stenosis and single chain rt-PA 
(Gl1035) at a rate of 30 &kg per min for 60 min in dogs with 
coronary artery stenosis. 
Pathologic examination. At the end of the experiment, the 
dogs were euthanized with an overdose of pentobarbital. 
The thrombosed, stenotic and poststenotic segments of the 
left anterior descending coronary artery were removed intact 
and fixed overnight in 5% formaldehyde. The left anterior 
descending coronary artery segment was sectioned at 2 mm 
intervals both through the zone with intimal damage and 
thrombosis and through the stenosis and poststenotic seg- 
ments. Sections were stained with hematoxylin-eosin and 
carefully examined microscopically for the presence of oc- 
clusive or nonocclusive thrombi. The relative amount of 
platelets, fibrin and red blood cells in the thrombotic material 
was evaluated. 
Results 
Coronary artery thrombolysis (Table 1). In the absence of 
the coronary artery stenosis, intravenous infusion of 750,000 
units of streptokinase over 1 h resulted in reperfusion in five 
of six dogs within 34 2 25 min (mean t SD). This was 
associated with a minor decrease in the fibrinogen level to 80 
2 25% of baseline. A combined intravenous and intracoro- 
nary infusion of urokinase produced reperfusion in three of 
four dogs within 65 -t 23 min, but was associated with total 
fibrinogen depletion. Two chain rt-PA (G11021), at a rate of 
15 pg/kg per min for 30 min or until reflow, resulted in 
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Table 1. Results of Coronary Artery Thrombolysis in 47 Dogs 
No. of Residual 
Reperfusion Reocclusion 
Fibrinogen 
Thrombolytic Agent 
Model without stenosis tn = 22) 
Streptokinase 
Urokinase 
rt-PA (G11021) 
Model with stenosis (n = 25) 
Streptokinase 
Urokinase 
rt-PA (Cl 1021) 
rt-PA (G11035) 
Dogs Flow (%) 
6 NA 
4 NA 
12 NA 
6 43 2 7 
6 40 ? 3 
5 40 + 3 
8 42 ? 4 
No. Time (min) 
5 34 ? 25 
3 65 ‘- 23 
I2 28 + 13 
2 40,78 
3 402 IO 
5 242 12 
6 28 i 30 
Flow t%) No. 
NA 0 
NA 0 
NA 0 
16,1X 2 
46 t I 3 
30 2 II 5 
44 ir 5 4 
Time (min) 
NA 
NA 
NA 
6, 11 
11 k 21 
I1 21 
625 
(% control) 
80 t 25 
Cl0 
77 + 23 
ND 
<lO 
ND 
65 t 26 
Streptokinase: 750.000 U intravenously over 1 h; urokinase: 600.000 U intravenously over 30 min followed by intracoronary administration of 600,000 U over 
30 mitt; two chain recombinant tissue-type plasminogen activator W-PA) (Cl 1021): I5 pgikg per min for 30 mitt or until reflow in dogs without stenosis and 15 
kg/kg per min for 30 min followed by 7.5 &kg per min for 30 min in dogs with stenosis; single chain rt-PA (G11035): 30 pg/kg per min for 60 min. Data are reported 
as mean values ? SD. NA = not applicable; ND = not determined. 
reperfusion in all 12 dogs within 28 2 13 min, without 
significant fibrinogen breakdown. Most significantly, in the 
absence of coronary artery stenosis, spontaneous reocclu- 
sion did not occur within a 2 h observation period. 
In the presence of the external coronary artery constric- 
tor in 25 dogs, which reduced the coronary artery blood flow 
to 41 ? 6% of the control value, all 10 dogs with coronary 
artery reperfusion induced by either streptokinase, uroki- 
nase or two chain rt-PA (G11021) and 4 of 6 dogs with 
reperfusion with one chain rt-PA (G11035) developed reoc- 
elusion spontaneously, generally within 30 min after the 
onset of reperfusion (Table 1). Reocclusion was frequently 
followed by brief cyclic periods of reflow interspersed with 
longer periods of occlusion (Fig. 3). Figure 4 represents 
typical electromagnetic flow probe tracings of coronary 
artery blood flow before constriction and after reduction of 
the blood flow with the external constrictor, after thrombosis 
Figure 4. Electromagnetic flow probe tracing of coronary artery 
blood flow in a dog infused with single chain rt-PA. A, Before 
constriction; B, after reduction of blood flow with the external 
constrictor; C, after thrombus formation; D, following thrombolysis 
and E, after reocclusion. 
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and after thrombolysis and reocclusion in a dog infused with 
single change rt-PA. 
Pathologic examination (Fig. 5). Microscopy of the coro- 
nary artery segments after successful reperfusion in dogs 
without coronary artery stenosis revealed only fibrin strands 
overlying a damaged intima without endothelium. In animals 
with coronary artery stenosis without reocclusion, mural 
thrombus overlying damaged intima was present either in the 
segment proximal to the stenosis or within the segment of 
the stenosis (Fig. 5A), or both. In animals with reocclusion, 
occlusive thrombus consisting of platelet-rich fibrin clots 
was consistently observed in the stenotic segment (Fig. 5C 
and D). 
Discussion 
Coronary artery reocclusion. Coronary artery reocclu- 
sion after successful thrombolysis with either streptokinase 
(4) or rt-PA (1,3) constitutes a significant limitation of 
thrombolytic therapy in patients with acute myocardial 
infarction. Major predisposing factors leading to reocclusion 
include 1) residual fixed high grade coronary artery stenosis, 
2) incomplete lysis with remaining thrombotic material, and 
3) a highly thrombogenic surface in the region of the dis- 
rupted endothelium overlying atheromatous plaque. 
Currently available animal models mainly consist of dogs 
with copper coil-induced coronary artery thrombosis (8) or 
with local thrombosis with endothelial damage by external 
trauma (1). These models do not adequately simulate the 
anatomic and pathophysiologic environment of coronary 
thrombosis leading to acute myocardial infarction in hu- 
mans. Consequently, it is not surprising that the high rate of 
reocclusion after coronary thrombolysis in humans has not 
been recognized or investigated in animal models. 
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Figure 5. Cross sections of the left anterior descending artery with 
postthrombotic segment stenosis subjected to thrombolysis. A, The 
stenotic segment of a dog treated with recombinant tissue plasmi- 
nogen activator without acute reocclusion. The section reveals loss 
of endothelium (compared with B) from intimal surface and small 
mural thrombi consisting of platelets and fibrin adherent to injured 
intima (arrows). B, From the poststenotic segment of the same 
artery shown in A. Note the presence of endothelial cells (arrows) 
clearly present on the luminal surface. C, Reoccluded left anterior 
descending artery reveals occlusive thrombus (T) in the stenotic 
segment. D, High magnification of C at area o reveals occlusive 
thrombus (T) composed mainly of platelets (PL), fibrin and a few red 
blood cells (R). The intimal surface is difficult to discern and is 
marked with arrows. M = media. Hematoxylin-eosin, magnification 
x500 (A, B, D) and x 125 (C); all reduced by 34%. 
Similarities between the dog model and patients with 
coronary artery thrombosis. The present model of coronary 
artery thrombosis in the setting of arterial wall injury and 
superimposed high grade stenosis more closely resembles 
the combination of factors underlying coronary thrombosis 
and reocclusion in humans. Indeed, elimination of the use of 
a thrombogenic intraluminal foreign body, abrasion of endo- 
thelium exposing subendothelial thrombogenic structures, 
uniform production of fixed high grade stenosis (>90%) and 
absence of spontaneous reflow constitute a reproducible 
quantitative model for the investigation of both coronary 
thrombolysis and approaches to prevent reocclusion. More- 
over, the mechanism of reocclusion, consisting of occlusive 
platelet-rich thrombus, is similar to that observed in humans. 
Coronary thrombolysis. The results of thrombolysis ob- 
tained by intravenous infusion of streptokinase, urokinase 
and recombinant rt-PA in this canine model parallel those 
obtained in humans. Indeed, streptokinase and urokinase 
have a more limited efficacy than does rt-PA (9,lO) and the 
two chain form of rt-PA has a somewhat higher in vivo 
potency than does the one chain form (11). requiring the use 
of a 15 to 2-fold higher dose of the latter molecular form. In 
addition, the invariable occurrence of reocclusion after 
thrombolysis parallels the observations in patients with high 
grade stenosis, in whom a >80% reduction of the luminal 
diameter frequently leads to coronary artery reocclusion (5). 
Clinical implications. Pathologic examination of the ma- 
terial responsible for reocclusion in the dog stenosis model 
reveals that it consists of a platelet-rich thrombus possibly of 
similar composition to the thrombolysis-sensitive material 
responsible for reocclusion in humans. On the basis of these 
observations, several hypotheses for the prevention of cor- 
onary reocclusion should be investigated. Neither full hep- 
arinization nor extensive fibrinogen depletion (for example. 
with urokinase) prevents reocclusion, a finding in agreement 
with observations made in human patients (4,12). We (13) 
have recently used this model to evaluate the efficacy of a 
monoclonal antibody directed against the platelet receptor 
GPlIblIIIa for the prevention of coronary artery reocclusion 
after reperfusion with intravenous rt-PA. 
Conclusions. This canine model of coronary artery throm- 
bosis and superimposed high grade stenosis may be useful 
for investigating factors influencing reocclusion, the efficacy 
of thrombolytic agents in terms of their specific thrombolytic 
activity and their potency to prevent reocclusion, and alter- 
native approaches to influence the thrombogenicity of the 
damaged endothelium or its interaction with thrombogenic 
components in the blood. 
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